Algernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sándor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke Study

Stock Information for Algernon Health Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Algernon Health Inc.

Algernon Closes Second Tranche of Private Placement Financing
Algernon Health and American Molecular Imaging Announce Strategic Business and USD $500K Investment Agreement
Algernon Closes First Tranche of its Recently Announced Private Placement Financing
Algernon Health Announces Private Placement
CSE Bulletin: Name Change - Algernon Pharmaceuticals Inc. (AGN)
Algernon Pharmaceuticals Completes Name Change to Algernon Health
Catalyst MedTech Launches "Connect" Program to Expand Access to Advanced Imaging; Announces Initial Partnership with Algernon Pharmaceuticals
Algernon Announces CAD $4 Million Non-Dilutive Financing to Open Four Brain-Specific PET Scan Clinics in the U.S. for Early Stage Alzheimer's Detection

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.